secwatch.observer — SEC 8-K summary
======================================

Issuer:     STAAR SURGICAL CO (STAA)
CIK:        0000718937
Form:       8-K/A
Filed at:   2026-10-05T16:25:39+00:00
Accession:  0001193125-26-413763
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

STAAR names ex-CEO David Bailey Chief Commercial Officer; equity awards total $2.25M
--------------------------------------------------------------------------------

- David Bailey named Chief Commercial Officer effective Sept 8, 2026, reporting to CEO Warren Foust; he was STAAR's President/CEO from 2001-2008 and later President, International.
- Base salary CHF 462,825 (~$575,000); FY2026 target bonus 60% of salary, prorated; initial equity grant $850,000, 50% RSUs and 50% options vesting over three years.
- 2026 annual long-term incentive award valued at $1,400,000, prorated, split 50% options/50% RSUs; plus standard executive severance and change-in-control terms.
- 8-K/A corrects the equity award mix from the Sept 10, 2026 original filing; dollar amounts unchanged, corrected offer letter filed as Exhibit 10.1.
- Press release cites Bailey's prior tenure: raised $60M+, won 2005 FDA approval of the ICL, launched in China and South Korea, and acquired the Canon Japan JV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/718937/000119312526413763/0001193125-26-413763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/718937/000119312526413763/staa-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-413763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer